Prostate-specific membrane antigen imaging should be the positron emission tomography imaging agent of choice for men who have a prostate cancer recurrence after radical prostatectomy, which needs to be detected and located. For these men, it should become the standard of care, new research shows.
A new deep learning algorithm, which demonstrates the potential of artificial Intelligence (AI) to support pathologists, has been developed for PD-L1 scoring in tumour cells and immune cells in urothelial carcinoma samples. Speaking at the Digital Pathology and Artificial Intelligence Congress in London last December, Dr Michel Vandenberghe, from AstraZeneca, outlined how PD-L1 expression level…
Wilmot Cancer Institute scientists believe they have figured out why a commonly used drug to treat late-stage prostate cancer often stops working after four or five months and appears to have a dual function that later turns the cancer into a relentless aggressor.
Pathologists, radiologists, urologists and radiotherapy specialists sit at the core of the treatment pathway for the patient, working together as a cohesive unit. In an innovative 2019 ECR session in Vienna, the prostate unit from Ghent University Hospital in Belgium outlined how the team works to deliver the best clinical outcome for patients. Session chair Professor Geert M Villeirs of Ghent…
Grocery store aisles are stocked with products that promise to kill bacteria. People snap up those items to protect themselves from the germs that make them sick. However, new research from Washington University in St. Louis finds that a chemical that is supposed to kill bacteria is actually making them stronger and more capable of surviving antibiotic treatment. The study, available online in…
Longer hours, more demanding working practices, complex cases and increased administration are taking their toll on physicians as growing numbers, across a range of specialties, report signs of burnout. All this despite technological advances such as artificial intelligence and machine learning to aid diagnosis, read and interpret images, improve workflow and enhance decision-making. Recognised…
Bracco Imaging S.p.A., a company in the diagnostic imaging business, announced today that its contrast agent SonoVue (sulphur hexafluoride microbubbles) is the first ultrasound contrast agent to obtain approval in the European Union for its use in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients.
The new product solutions of medical technology company Richard Wolf were presented at the Congress of the European Association of Urology (EAU) in several live operations and pre-recorded videos.
New research confirms that an innovative procedure combining MRI and ultrasound to create a 3D image of the prostate can more accurately locate suspicious areas and help diagnose whether it’s prostate cancer.
Men with very high-risk prostate cancer, who are treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy), only have half of the mortality risk of men who are treated at hospitals with the lowest proportion. This is according to a new study conducted by researchers at Umeå University in Sweden.
Ultrasound biopsy is rather unreliable to detect or exclude prostate cancer: many tumours are difficult – or impossible – to visualise sonographically and tissue sampling is haphazard rather than targeted.
A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Urinary tract infections caused by catheterisation are a common and nasty affliction for the disabled, elderly and hospital patients.